Zafgen Finds Plentiful Funding in Slimmed Down Obesity Market
This article was originally published in Start Up
Executive Summary
The obesity-foucsed start-up Zafgen has emerged from stealth mode. Taking the reins as CEO is Thomas Hughes, PhD, former VP and global head of cardiovascular and metabolic disease at Novartis. With $22 million in funding from Atlas Venture and Third Rock Ventures, the company is well capitalized to drive its lead molecules into the clinic.
You may also be interested in...
Diabetes Drug Development: Seeing Light In The Dark Ages?
Tougher regulatory hurdles introduced three years ago extended the timelines for successful diabetes drug development, discouragiing investment and partnering activity. An ever-increasing incidence of diabetes, metabolic disorders, and obesity continues to drive innovation and the development of new medicines – but with less emphasis on novel mechanisms.
Obesity-Focused Zafgen Raises Zaftig Series B
Three years after its launch, Zafgen emerges from stealth mode with a new CEO and another $14 million in funding.
Obesity-Focused Zafgen Raises Zaftig Series B
Three years after its launch, Zafgen emerges from stealth mode with a new CEO and another $14 million in funding.